Search clinical trials for: Factor XIIa antagonist monoclonal antibody

Total 8065 results

Chen Xiaoping

Recruiting

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

HCC

China
Institute of Hematology & Blood Diseases Hospital...
Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaborators

Recruiting

TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)

China
M.D. Anderson Cancer Center

Active, not recruiting

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Recurrent T-Cell Prolymphocytic Leukemia | T-Cell Prolymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Ludwig Institute for Cancer Research
Medarex

Terminated

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Synovial Sarcoma

United States
George W. Sledge Jr.
National Cancer Institute (NCI)

Completed

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
Amgen

Completed

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

Stomatitis
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM310 in Patients With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Bio-Thera Solutions

Active, not recruiting

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China

Advanced Solid Tumors

China
Dragonboat Biopharmaceutical Company Limited
Fudan University

Recruiting

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Bladder Cancer | Renal Carcinoma | Advanced Penile Carcinoma

China
Sun Yat-sen University

Recruiting

Ablation Combined With PD-1 in HCC: Phase II Study

Hepatocellular Carcinoma

China
Zhejiang University

Recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Pancreatic Cancer

China
Synermore Biologics (Suzhou) Co., Ltd.

Completed

A Bridging Study of the SYN023 on Healthy Adult Subjects

Vaccine Reaction | Rabies Human | Immunisation Reaction | Zoonotic Disease | Communicable Disease Transmission

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0916, MLN1202 in Treating Patients With Bone Metastases

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
Sinocelltech Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Hoffmann-La Roche
University of Pennsylvania

Completed

A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

Pancreatic Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

Advanced Melanoma | Kidney Cancer Stage Iv

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma

Bladder Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Metastatic Melanoma | Advanced Melanoma

China
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma

Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) (CLANC)

Nasopharyngeal Cancer | EBV Infections

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
CSL Behring

Completed

Effects of CSL324 in the Lung After Segmental Challenge

Healthy Volunteers

Germany
Sohag University

Recruiting

Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris

Healthy | Verruca Vulgaris

Egypt
Beijing Dongfang Biotech Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

NSCLC
ChemomAb Ltd.

Active, not recruiting

CM-101 in PSC Patients -The SPRING Study

Primary Sclerosing Cholangitis

United States, Germany, Israel, Spain, United Kingdom
ChemomAb Ltd.

Completed

Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

Healthy

Israel
Second Affiliated Hospital, School of Medicine,...

Enrolling by invitation

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma (CICPD)

Diffuse Large B-cell Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Sarcoma | Lung Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Duke University

Completed

Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas

Brain and Central Nervous System Tumors

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Biotech Pharmaceutical Co., Ltd.

Terminated

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

Psoriasis

China
Rockefeller University

Completed

3BNC117-LS First-in-Human Phase 1 Study

Human Immunodeficiency Virus

United States
Lee's Pharmaceutical Limited

Unknown

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

AMD

China
Jonsson Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Active, not recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8

United States
Case Comprehensive Cancer Center

Terminated

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

Cholangiocarcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage... and other conditions

United States
Changhai Hospital

Not yet recruiting

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody (PMMR/MSS)

Rectal Cancer
Great Ormond Street Hospital for Children NHS Foundation...

Recruiting

90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (RITII)

Leukemia

United Kingdom
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Follicular Lymphoma and Marginal Zone Lymphoma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

HER2-positive Recurrent or Metastatic Malignant Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
University of Tennessee
FDA Office of Orphan Products Development

Completed

Radioimmunoimaging of AL Amyloidosis

Primary Amyloidosis

United States
PDL BioPharma, Inc.

Completed

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States

Search clinical trials for: Factor XIIa antagonist monoclonal antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations